StockNews.com Begins Coverage on Diffusion Pharmaceuticals (NASDAQ:DFFN)
StockNews.com Begins Coverage on Diffusion Pharmaceuticals (NASDAQ:DFFN)
Equities researchers at StockNews.com initiated coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.
Separately, HC Wainwright upgraded shares of Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price objective for the company in a research report on Tuesday, August 16th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Stock Up 3.3 %
Shares of Diffusion Pharmaceuticals stock opened at $6.30 on Thursday. Diffusion Pharmaceuticals has a fifty-two week low of $5.10 and a fifty-two week high of $28.25. The business has a 50-day moving average price of $7.01 and a 200 day moving average price of $11.48. The firm has a market cap of $12.85 million, a P/E ratio of -0.51 and a beta of 1.53.
Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($2.06) EPS for the quarter, missing analysts' consensus estimates of ($1.77) by ($0.29). As a group, equities research analysts anticipate that Diffusion Pharmaceuticals will post -8.43 earnings per share for the current year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP acquired a new position in shares of Diffusion Pharmaceuticals in the 2nd quarter valued at about $71,000. JPMorgan Chase & Co. purchased a new stake in shares of Diffusion Pharmaceuticals during the first quarter worth $106,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Diffusion Pharmaceuticals by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock valued at $331,000 after purchasing an additional 101,100 shares during the last quarter. Hedge funds and other institutional investors own 10.25% of the company's stock.
Diffusion Pharmaceuticals Company Profile
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Featured Stories
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com的股票研究人员发起了对扩散制药(纳斯达克:DFFN-GET评级)在周四发布给投资者的一份研究报告中。该经纪公司对该股设定了“持有”评级。
另外,在8月16日(周二)的一份研究报告中,HC Wainwright将Diffsion PharmPharmticals的股票评级从中性上调至买入,并为该公司设定了9.50美元的目标价。
到达扩散制药公司警报:扩散制药类股上涨3.3%
周四,扩散制药公司的股票开盘报6.30美元。Diffect PharmPharmticals的52周低点为5.10美元,52周高位为28.25美元。该业务的50日移动均线价格为7.01美元,200日移动均线价格为11.48美元。该公司市值为1285万美元,市盈率为-0.51,贝塔系数为1.53。
扩散制药(纳斯达克:DFFN-GET评级)最近一次发布季度收益报告是在8月11日(星期四)。该公司公布本季度每股收益为2.06美元,低于分析师普遍预期的每股收益1.77美元和0.29美元。作为一个整体,股票研究分析师预计,扩散制药公司本年度的每股收益将达到8.43美元。机构资金流入和流出
机构投资者和对冲基金最近调整了对该公司的持股。Trexquant Investment LP在第二季度收购了扩散制药公司股票的新头寸,价值约7.1万美元。摩根大通(JPMorgan Chase&Co.)在第一季度购入了价值10.6万美元的新股。最后,复兴科技有限责任公司在第一季度增持了8.3%的扩散制药股份。复兴科技有限责任公司在上个季度又购买了101,100股后,现在拥有1,324,202股该公司股票,价值331,000美元。对冲基金和其他机构投资者持有该公司10.25%的股票。
扩散制药公司简介
(获取评级)
扩散制药公司是一家生物制药公司,该公司开发新的疗法,以增强人体输送氧气的能力。它的主要候选产品是反式番茄酸钠,开发这种药物是为了促进氧气向组织的扩散,以及治疗新冠肺炎病。扩散制药公司成立于2001年,总部设在弗吉尼亚州夏洛茨维尔。
专题报道
- 免费获取StockNews.com关于扩散药物的研究报告(DFFN)
- 这家医疗设备制造商准备好继续反弹了吗?
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马?
- 具有有趣内幕活动的四只廉价股票
- 随着收购传言的甚嚣尘上,Lyft能否成功?
获得《扩散医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对扩散制药及相关公司评级的每日简要摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧